When was Accipiter Biosciences founded?

Accipiter Biosciences was founded in 2023 and raised its 1st funding round 2 years after it was founded.

Where is Accipiter Biosciences located?

Accipiter Biosciences is headquartered in Seattle, United States.

Who is the current CEO of Accipiter Biosciences?

Matthew J Bick and Bill Arthur s of Accipiter Biosciences. Matthew J Bick has also founded 1 company.

How many employees does Accipiter Biosciences have?

As of Mar 31, 2026, the latest employee count at Accipiter Biosciences is 24.

Is Accipiter Biosciences a funded company?

Accipiter Biosciences is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Nov 07, 2025.

When was the latest funding round of Accipiter Biosciences?

Accipiter Biosciences' latest funding was a $***** Seed round on Nov 07, 2025, with participation from 8 investors.

Where does Accipiter Biosciences rank among its competitors?

Accipiter Biosciences ranks 913th amongst 3545 active competitors, of which 1237 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Accipiter Biosciences, which secured $12.7M in Nov, 2025.

Who are the top competitors of Accipiter Biosciences?

Accipiter Biosciences' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Accipiter Biosciences secured the most recent funding round in November, 2025.

Accipiter Biosciences - 2026 Company Profile, Team, Funding & Competitors

Accipiter Biosciences is a seed company based in Seattle (United States), founded in 2023 by Matthew J Bick, Hector Rincon, Bill Arthur and Javier Castellanos. It operates as a Developer of de novo protein therapies for complex diseases treatment. Accipiter Biosciences has raised $12.7M in funding from Takeda and Flying Fish Ventures. The company has 3545 active competitors, including 1237 funded and 825 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of de novo protein therapies for complex diseases treatment. These single-agent biologics are custom-engineered to engage multiple pathways. The biologics combine multiple mechanisms in one stable protein molecule. Therapeutic candidates activate more than one cell-surface receptor on the same cell. The platform uses computational methods to create customizable, multifunctional proteins. The company advances a pipeline in autoimmunity and oncology.

Website: accipiterbio.com
Email ID: *****@accipiterbio.com

Key Metrics

Founded Year

2023

Location

Seattle, United States

Stage

Seed

Total Funding

$12.7M in 1 round

Latest Funding Round

Seed, Nov 07, 2025, $*****

Investors

Takeda & 7 more

Ranked

913^th among 3545 active competitors

Employee Count

24 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3390 more

View Accipiter Biosciences' full profile

Accipiter Biosciences has raised a total funding of $12.7M over 1 round. Its latest funding round was a Seed round on Nov 07, 2025 for $*****. 8 investors participated in its latest round. Accipiter Biosciences has 8 institutional investors.

Here is the list of recent funding rounds of Accipiter Biosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 07, 2025	8425071	Seed	4787086	4274482	8742802	8870254

Access funding benchmarks and valuations. Sign up today!

View details of Accipiter Biosciences's funding rounds and investors

The founders of Accipiter Biosciences are Matthew J Bick, Hector Rincon, Bill Arthur and Javier Castellanos. Bill Arthur and Matthew J Bick are the CEOs of Accipiter Biosciences.

Here are the details of Accipiter Biosciences' key team members:

Matthew J Bick: Co-Founder & CEO of Accipiter Biosciences.
Contact Info: 1 email address
Hector Rincon: Co-Founder & CSO of Accipiter Biosciences.
Bill Arthur: Co-Founder & CEO of Accipiter Biosciences.
Javier Castellanos: Co-Founder & CTO of Accipiter Biosciences.
Contact Info: 1 email address

View details of Accipiter Biosciences's Founder profiles and Board Members

Accipiter Biosciences' employee count trend

Accipiter Biosciences has 24 employees as of Mar 26. Here is Accipiter Biosciences's employee count trend over the years:

Employee count trend for Accipiter Biosciences

Uncover Accipiter Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Accipiter Biosciences include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Accipiter Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Google Ventures, Baillie Gifford & 17 others	75/100
4th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, PMV & 20 others	74/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	73/100
6th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	73/100
7th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
8th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
9th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
10th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 18 others	72/100
913th	Accipiter Biosciences 2023, Seattle (United States), Seed	Developer of de novo protein therapies for complex diseases treatment	$12.7M	Takeda, Columbus Venture Partners & 6 others	45/100